ROIV ▲ +2.5% - Roivant Sciences Ltd. $ROIV ROIVW - Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study Roivant Sciences rose 2.5% following announcement of positive results from its PHocus Study evaluating mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, a rare and serious condition with limited treatment options. The company also disclosed progress on its ongoing Phase 3 PHrontier Study, signaling advancement in its clinical pipeline for this indication. 08-SEP-2026 06:00 AM ET